As of May 25
| +4.91 / +26.63%|
The 13 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 10.00, with a high estimate of 60.00 and a low estimate of 4.00. The median estimate represents a -57.17% decrease from the last price of 23.35.
The current consensus among 14 polled investment analysts is to Hold stock in Sarepta Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.